ArrayExpress is moving to BioStudies. This view of ArrayExpress will be deprecated soon.
Please visit the new experiment page at https://www.ebi.ac.uk/biostudies/arrayexpress/studies/E-MTAB-7721.
E-MTAB-7721 - The LL-100 panel: 100 DSMZ cell lines for blood cancer studies; RNA-Seq
Released on 28 May 2019, last updated on 1 November 2019
For many years, immortalized cell lines have been used as model systems for cancer research. Cell line panels were established for basic research and drug development, but did not cover the full spectrum of leukemia and lymphoma. Therefore, we now developed a novel panel (LL-100), 100 cell lines covering 22 entities of human leukemia and lymphoma including T-cell, B-cell and myeloid malignancies. Importantly, all cell lines are unequivocally authenticated and assigned to the correct tissue. Cell line samples were proven to be free of mycoplasma and virus contamination. Whole exome sequencing (WES) and RNA sequencing (RNA-seq) of the hundred authenticated leukemia-lymphoma cell lines were conducted with a uniform methodology to complement existing data on these publicly available cell lines. This part captures RNA-Seq. This data set will be useful for understanding the function of oncogenes and tumor suppressor genes and to develop targeted therapies.
RNA-seq of coding RNA, disease state design, strain or line design
The LL-100 panel: 100 cell lines for blood cancer studies. Quentmeier H, Pommerenke C, Dirks WG, Eberth S, Koeppel M, MacLeod RAF, Nagel S, Steube K, Uphoff CC, Drexler HG. 9(1):8218 (2019), PMID:31160637